Takeda Pharmaceutical Company Limited
HealthcareNYSE:TAK · New York Stock Exchange
+$0.04 today
Vol 3.76M · Avg 3.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.6%
avg 4.1%
ROIC
3.1%
avg 2.8%
ROA
1.3%
avg 1.9%
Analysis
ROIC is currently the strongest return metric at 3.1% versus its period average of 2.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christophe Weber | President, Chief Executive Officer & Representative Director | $5.18M | — | 60 | $0.00 | <0.01% |
Andrew S. Plump | President of Research & Development and Representative Director | $3.58M | — | 61 | $806,572.00 | 0.03% |
Milano Furuta | Chief Financial Officer & Director | $1.45M | — | 48 | $0.00 | <0.01% |
Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy | — | — | 51 | — | — |
Norimasa Takeda | Chief Accounting Officer & Corporate Controller | — | — | — | — | — |
Michael Fox | Chief Operating Officer | — | — | — | — | — |
Gabriele Ricci | Chief Data & Technology Officer | — | — | 48 | $159,126.00 | <0.01% |
Haruhiko Hirate | Member of Management Board | — | — | 69 | — | — |
Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department | — | — | — | — | — |
Christopher David O'Reilly | Global Head of Investor Relations & Global Finance | — | — | — | — | — |
Seigo Izumo | Chair of Management Board | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -18.5% | +5.4% (16yr)1 analysts |
| Revenue | N/A | N/A | +5.1% | +6.8% (16yr)3 analysts |
| Net Income | N/A | N/A | -15.2% | +10.2% (16yr)3 analysts |
| EBIT | N/A | N/A | +2.2% | +10.8% (16yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.1% over three years. Forward estimates point to EBIT at +10.8% (16yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.98B
Cardinal Health, Inc.
NYSE:CAH
$52.43B
Edwards Lifesciences Corporation
NYSE:EW
$49.01B
Haleon plc
NYSE:HLN
$40.31B
Agilent Technologies, Inc.
NYSE:A
$36.67B
Alcon Inc.
NYSE:ALC
$32.58B
IQVIA Holdings Inc.
NYSE:IQV
$30.29B
ResMed Inc.
NYSE:RMD
$28.25B
Veeva Systems Inc.
NYSE:VEEV
$25.92B
Insmed Incorporated
NASDAQ:INSM
$21.21B
Who manages TAK?
Takeda Pharmaceutical Company Limited (TAK) lists 11 active executives. The top listed executive is Milano Furuta, Chief Financial Officer & Director.
Are TAK insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.